Akebia Therapeutics (AKBA) Reports Q4 results

Akebia Therapeutics (NASDAQ: AKBA) reported Q4 Revenue for the quarter at $56.2 million versus the consensus estimate of $55.89 million.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.

You May Also Be Interested In

• Ennis (EBF) Reports In-Line Q1 EPS
• Micron Technology (MU) PT Raised to $1,300 at Bernstein SocGen Group
• Wall Street scrambles to lift Micron price targets ahead of earnings